Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)

DRUG2 trials

Sponsors

GE Healthcare, Roderick Tan

Conditions

End Stage Chronic Renal FailureMicrovascular ChangesMicrovascular CirculationPulmonary HypertensionRenal Transplant

Phase 4

Evaluate Effect of Optison on Pulmonary Artery Systolic Pressure (PASP) and Pulmonary Vascular Resistance (PVR).

CompletedNCT00878878

GE HealthcarePulmonary Hypertension

Start: 2009-03-31End: 2010-07-31Updated: 2012-08-24

Unknown Phase

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

Not yet recruitingNCT07645599

Roderick TanEnd Stage Chronic Renal Failure, Microvascular Changes, Microvascular Circulation +1

Start: 2026-06-01End: 2028-06-30Target: 40Updated: 2026-06-12